Literature DB >> 12352015

CD14 signalling in lipid rafts: new ligands and co-receptors.

Gerd Schmitz1, Evelyn Orsó.   

Abstract

PURPOSE OF REVIEW: Lipid rafts on monocytes/macrophages provide a dynamic microenvironment for an integrated lipopolysaccharide receptor (CD14)-dependent clustering of a set of receptors involved in innate immunity and clearance of atherogenic lipoproteins. The purpose of this review is to summarize the recent advances in our understanding of CD14-dependent receptor clustering and its relevance in atherogenesis. RECENT
FINDINGS: Upon binding of various ligands, CD14 as a multiligand pattern recognition receptor induces specific coassembly of additional receptors present on circulating monocytes.
SUMMARY: The composition of the receptor cluster and thus the associated signalling pathways defines a ligand specific cellular response, linking endogenous and exogenous host defense to a common recognition platform in rafts.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12352015     DOI: 10.1097/00041433-200210000-00007

Source DB:  PubMed          Journal:  Curr Opin Lipidol        ISSN: 0957-9672            Impact factor:   4.776


  34 in total

Review 1.  Role of lipid rafts in liver health and disease.

Authors:  Angela Dolganiuc
Journal:  World J Gastroenterol       Date:  2011-05-28       Impact factor: 5.742

Review 2.  Crosstalk between reverse cholesterol transport and innate immunity.

Authors:  Kathleen M Azzam; Michael B Fessler
Journal:  Trends Endocrinol Metab       Date:  2012-03-10       Impact factor: 12.015

3.  Detecting and quantifying colocalization of cell surface molecules by single particle fluorescence imaging.

Authors:  Ian E G Morrison; Ioannis Karakikes; Rosamund E Barber; Nelson Fernández; Richard J Cherry
Journal:  Biophys J       Date:  2003-12       Impact factor: 4.033

Review 4.  The SYK side of TLR4: signalling mechanisms in response to LPS and minimally oxidized LDL.

Authors:  Yury I Miller; Soo-Ho Choi; Philipp Wiesner; Yun Soo Bae
Journal:  Br J Pharmacol       Date:  2012-11       Impact factor: 8.739

5.  Inhibition of Neuroinflammation by AIBP: Spinal Effects upon Facilitated Pain States.

Authors:  Sarah A Woller; Soo-Ho Choi; Eun Jung An; Hann Low; Dina A Schneider; Roshni Ramachandran; Jungsu Kim; Yun Soo Bae; Dmitri Sviridov; Maripat Corr; Tony L Yaksh; Yury I Miller
Journal:  Cell Rep       Date:  2018-05-29       Impact factor: 9.423

6.  Toll-like receptor (TLR) 3 immune modulation by unformulated small interfering RNA or DNA and the role of CD14 (in TLR-mediated effects).

Authors:  Cordula Weber; Christian Müller; Anja Podszuweit; Carmen Montino; Jörg Vollmer; Alexandra Forsbach
Journal:  Immunology       Date:  2012-05       Impact factor: 7.397

7.  AIBP augments cholesterol efflux from alveolar macrophages to surfactant and reduces acute lung inflammation.

Authors:  Soo-Ho Choi; Aaron M Wallace; Dina A Schneider; Elianne Burg; Jungsu Kim; Elena Alekseeva; Niki Dj Ubags; Carlyne D Cool; Longhou Fang; Benjamin T Suratt; Yury I Miller
Journal:  JCI Insight       Date:  2018-08-23

8.  Quantitative proteomics analysis of macrophage rafts reveals compartmentalized activation of the proteasome and of proteasome-mediated ERK activation in response to lipopolysaccharide.

Authors:  Suraj Dhungana; B Alex Merrick; Kenneth B Tomer; Michael B Fessler
Journal:  Mol Cell Proteomics       Date:  2008-09-23       Impact factor: 5.911

9.  Tuning innate immune activation by surface texturing of polymer microparticles: the role of shape in inflammasome activation.

Authors:  Christine A Vaine; Milan K Patel; Jintao Zhu; Eunji Lee; Robert W Finberg; Ryan C Hayward; Evelyn A Kurt-Jones
Journal:  J Immunol       Date:  2013-02-20       Impact factor: 5.422

10.  CD14 is a coreceptor of Toll-like receptors 7 and 9.

Authors:  Christoph L Baumann; Irene M Aspalter; Omar Sharif; Andreas Pichlmair; Stephan Blüml; Florian Grebien; Manuela Bruckner; Pawel Pasierbek; Karin Aumayr; Melanie Planyavsky; Keiryn L Bennett; Jacques Colinge; Sylvia Knapp; Giulio Superti-Furga
Journal:  J Exp Med       Date:  2010-11-15       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.